<DOC>
	<DOC>NCT00335452</DOC>
	<brief_summary>The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).</brief_summary>
	<brief_title>Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS</brief_title>
	<detailed_description />
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina, Unstable</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Diagnosed with acute coronary disease with clinical symptoms and at least electrocardiogram changes or cardiac enzymes elevated Use of anticoagulants within 10 days with an international normalized ratio (INR) &gt; 1.5 or planned use during the hospitalisation period Administration of clopidogrel &gt; 75 mg prior to randomization Contraindication to clopidogrel or aspirin Active bleeding or significant risk of bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>platelet aggregation inhibitors</keyword>
	<keyword>acute coronary disease</keyword>
	<keyword>percutaneous coronary</keyword>
</DOC>